Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 1, 2024Journal of Clinical Oncology

ARV-766, a proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC): Initial results of a phase 1/2 study.

View Full Paper
Ask AI
Bookmark
Share

Authors

DPDaniel P. PetrylakMMMeredith McKeanJLJoshua M. Lang

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Petrylak et al. (2024) studied this question.

synapsesocial.com/papers/68e669a9b6db6435875f58dfhttps://doi.org/10.1200/jco.2024.42.16_suppl.5011
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1MP14-19 ARV-766, A PROTAC ANDROGEN RECEPTOR (AR) DEGRADER, COMBINED WITH ABIRATERONE IN NOVEL HORMONAL AGENT (NHA)-NAÏVE METASTATIC PROSTATE CANCER: PHASE 1 COHORT (PART C) OF A PHASE 1/2 STUDY2024
  2. 2Biomarker assessment and pharmacology of HP518, an AR PROTAC degrader from the phase 1 dose-escalation study in patients with metastatic castration-resistant prostate cancer (mCRPC).2024 · 2 citations
  3. 3HRS-5041, an androgen receptor degrader, in metastatic castration-resistant prostate cancer: A phase 1, multicenter, first-in-human study.2026
  4. 4Phase 1, multicenter, open-label study of HSK46575 in patients with metastatic castration-resistant prostate cancer progressing after next-generation hormonal agents and chemotherapy.2026
  5. 5CYP11A1 inhibitor MK-5684 versus next-generation hormonal agent (NHA) switch in patients with metastatic castration-resistant prostate cancer (mCRPC) after 1 prior NHA: Phase 3 MK-5684-004 study.2024 · 1 citations